(NASDAQ: NXTC) Nextcure's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Nextcure's earnings in 2025 is -$58,011,000.On average, 5 Wall Street analysts forecast NXTC's earnings for 2025 to be -$43,470,465, with the lowest NXTC earnings forecast at -$56,700,210, and the highest NXTC earnings forecast at -$16,685,912. On average, 5 Wall Street analysts forecast NXTC's earnings for 2026 to be -$22,477,811, with the lowest NXTC earnings forecast at -$23,137,047, and the highest NXTC earnings forecast at -$21,610,085.
In 2027, NXTC is forecast to generate -$9,484,962 in earnings, with the lowest earnings forecast at -$9,113,003 and the highest earnings forecast at -$9,763,931.